Top

Radiation Oncology

Published in:

Open Access 01-12-2019 | Breast Cancer | Research

Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer

Authors: Tobias Finazzi, Van-Trinh Nguyen, Frank Zimmermann, Alexandros Papachristofilou

Published in: Radiation Oncology | Issue 1/2019

Abstract

Purpose

The heart and lungs are routinely exposed to incidental irradiation during adjuvant radiotherapy (RT) of breast cancer. We analyzed the impact of patient and treatment characteristics on heart and lung dose in left-sided breast RT.

Methods

We analyzed 332 female patients treated with left-sided breast RT between 2013 and 2018. Mean heart dose (MHD), left mean lung dose (MLD) and heart / lung V_20Gy were collected from treatment plans. Patients were stratified by RT technique (3D-conformal RT, 3DCRT; intensity-modulated RT, IMRT; volumetric modulated arc therapy, VMAT) and target volumes, including lymph node RT (LN-RT). Patient characteristics (body mass index (BMI), heart and lung volume) were assessed using correlation analyses.

Results

LN-RT was performed in 111 patients with increased MHD (median 4.6 vs. 3.3 Gy; p < .01), left MLD (14.8 vs. 7.7 Gy; p < .01) and left lung V_20Gy (30.0% vs. 14.4%; p < .01) compared to treatment without LN-RT. Internal mammary LN-RT further increased organ doses compared to RT involving only supraclavicular +/− axillary LN (p < .01 for all values; MHD 6.9 vs. 4.2 Gy). In 221 patients treated without LN-RT, IMRT/VMAT was associated with higher left lung doses (MLD 9.1 vs. 7.4 Gy, p < .01; V_20Gy 18.8% vs. 14.0%, p < .01) compared to 3DCRT. A negative correlation between total lung volume and both MHD (r = − 0.38; p < .01) and heart V_20Gy (r = − 0.37; p < .01), as well as a weak positive correlation of BMI and MHD (r = 0.27; p < .01) were observed.

Conclusions

In adjuvant RT for left-sided breast cancer, LN-RT is associated with a marked increase in heart and lung doses, particularly with internal mammary LN-RT. Potential advantages of IMRT/VMAT for breast or chest wall RT need to be weighed against a moderately increased lung dose.

Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.CrossRef

P. M, C. T, S. D. Effect of radiotherapy after mastectomy and axillary dissection on recurrence and breast cancer mortality: meta-analysis of individual patient data from randomised trials. Eur J Cancer. 2014;50:S102.

Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98. https://doi.org/10.1056/NEJMoa1209825.CrossRefPubMed

Taylor C, Correa C, Duane FK, et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641–9. https://doi.org/10.1200/JCO.2016.72.0722.CrossRefPubMedPubMedCentral

Boero IJ, Paravati AJ, Triplett DP, et al. Modern radiation therapy and cardiac outcomes in breast cancer. Int J Radiat Oncol Biol Phys. 2016;94:700–8. https://doi.org/10.1016/j.ijrobp.2015.12.018.CrossRefPubMed

Kwa SLS, Lebesque JV, Theuws JC, Marks LB. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9.CrossRef

Aznar MC, Duane FK, Darby SC, et al. Exposure of the lungs in breast cancer radiotherapy: a systematic review of lung doses published 2010-2015. Radiother Oncol. 2018;126:148–54. https://doi.org/10.1016/j.radonc.2017.11.022.CrossRefPubMedPubMedCentral

Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114:3–10. https://doi.org/10.1016/j.radonc.2014.11.030.CrossRefPubMed

Marks L, Bentzen S, Deasy J, Kong F. Radiation dose volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76:70–6. https://doi.org/10.1016/j.ijrobp.2009.06.091.Radiation.CrossRef

10.

NCCN. National Comprehensive Cancer Network Guidelines Version 3.2018: Breast Cancer; 2018. https://doi.org/10.1007/978-1-4614-8063-1.CrossRef

11.

Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–v30. https://doi.org/10.1093/annonc/mdw324.CrossRefPubMed

12.

S3-Leitlinien (2018) Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms (Version 4.1). https://doi.org/10.3238/arztebl.2018.0316

13.

Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast Cancer. N Engl J Med. 2015;373:317–27. https://doi.org/10.1056/NEJMoa1415369.CrossRefPubMed

14.

Whelan TJ, Olivotto I a, Parulekar WR, et al. Regional nodal irradiation in early-stage breast Cancer. N Engl J Med. 2015;373:307–16. https://doi.org/10.1056/NEJMoa1415340.CrossRefPubMedPubMedCentral

15.

Budach W, Kammers K, Boelke E, Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials. Radiat Oncol. 2013;8(267). https://doi.org/10.1186/1748-717X-8-267.

16.

Hennequin C, Bossard N, Servagi-Vernat S, et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2013;86:860–6. https://doi.org/10.1016/j.ijrobp.2013.03.021.CrossRefPubMed

17.

Thorsen LBJ, Offersen BV, Dano H, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast Cancer. J Clin Oncol. 2016;34:314–20. https://doi.org/10.1200/JCO.2015.63.6456.CrossRef

18.

Taylor CW, Zhe W, Macaulay E, et al. Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys. 2015;93:845–53. https://doi.org/10.1016/j.ijrobp.2015.07.2292.CrossRefPubMed

19.

Hong JC, Rahimy E, Gross CP, et al. Radiation dose and cardiac risk in breast cancer treatment: an analysis of modern radiation therapy including community settings. Pract Radiat Oncol. 2018;8:e79–86. https://doi.org/10.1016/j.prro.2017.07.005.CrossRefPubMed

20.

Pierce LJ, Feng M, Griffith KA, et al. Recent time trends and predictors of heart dose from breast radiation therapy in a large quality consortium of radiation oncology practices. Int J Radiat Oncol Biol Phys. 2012;99:1154–61. https://doi.org/10.1016/j.ijrobp.2017.07.022.CrossRef

21.

Chan TY, Tan PW, Tang JI. Intensity-modulated radiation therapy for early-stage breast cancer: is it ready for prime time? Breast Cancer(Dove Med Press). 2017;9:177–83. https://doi.org/10.2147/BCTT.S127583.CrossRef

22.

Ayata HB, Güden M, Ceylan C, et al. Comparison of dose distributions and organs at risk (OAR) doses in conventional tangential technique (CTT) and IMRT plans with different numbers of beam in left-sided breast cancer. Rep Pract Oncol Radiother. 2011;16:95–102. https://doi.org/10.1016/j.rpor.2011.02.001.CrossRefPubMedPubMedCentral

23.

Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol. 2013;31:4488–95. https://doi.org/10.1200/JCO.2013.49.7842.CrossRefPubMed

24.

Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23:7475–82. https://doi.org/10.1200/JCO.2005.13.755.CrossRefPubMed

25.

Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–24. https://doi.org/10.1093/jnci/dji067.CrossRefPubMedPubMedCentral

26.

Weberpals J, Jansen L, Müller OJ, Brenner H. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39:3896–3903. https://doi.org/10.1093/eurheartj/ehy167.CrossRef

27.

Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–8. https://doi.org/10.1016/j.ijrobp.2009.10.058.CrossRefPubMed

28.

Duma MN, Herr A-C, Borm KJ, et al. Tangential field radiotherapy for breast Cancer—the dose to the heart and heart subvolumes: what structures must be contoured in future clinical trials? Front Oncol. 2017;7:1–6. https://doi.org/10.3389/fonc.2017.00130.CrossRef

29.

Taylor C, McGale P, Brønnum D, et al. Cardiac structure injury after radiotherapy for breast cancer: cross-sectional study with individual patient data. J Clin Oncol. 2018;36:2288–96. https://doi.org/10.1200/JCO.2017.77.6351.CrossRefPubMedPubMedCentral

30.

Nguyen MH, Lavilla M, Kim JN, Fang LC. Cardiac sparing characteristics of internal mammary chain radiotherapy using deep inspiration breath hold for left-sided breast cancer. Radiat Oncol. 2018;13:1–8. https://doi.org/10.1186/s13014-018-1052-8.CrossRef

31.

Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol. 2013;106:28–32. https://doi.org/10.1016/j.radonc.2012.10.016.CrossRefPubMed

32.

Remouchamps VM, Vicini FA, Sharpe MB, et al. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. Int J Radiat Oncol Biol Phys. 2003;55:392–406. https://doi.org/10.1016/S0360-3016(02)04143-3.CrossRefPubMed

33.

Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–60. https://doi.org/10.1016/S0140-6736(17)31145-5.CrossRef

34.

Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a ran. Lancet. 2016;387:229–38. https://doi.org/10.1016/S0140-6736(15)00471-7.CrossRefPubMed

35.

Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer:5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–13. https://doi.org/10.1016/S0140-6736(13)61950-9.CrossRefPubMed

Title: Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer
Authors: Tobias Finazzi
Van-Trinh Nguyen
Frank Zimmermann
Alexandros Papachristofilou
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Published in: Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-019-1364-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Biophysical modeling and experimental validation of relative biological effectiveness (RBE) for 4He ion beam therapy

Single isocenter stereotactic radiosurgery for patients with multiple brain metastases: dosimetric comparison of VMAT and a dedicated DCAT planning tool

Left breast irradiation with tangential intensity modulated radiotherapy (t-IMRT) versus tangential volumetric modulated arc therapy (t-VMAT): trade-offs between secondary cancer induction risk and optimal target coverage

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Long-term functional outcome after laryngeal cancer treatment

Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study